Filing Analysis
Dogwood Therapeutics, Inc. filed an 8-K to announce its second quarter 2026 financial results for the period ended June 30, 2026.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Dogwood Therapeutics held its annual meeting of stockholders on June 16, 2026, where shareholders approved an amendment to the Certificate of Incorporation to increase the number of authorized common and preferred shares. The company also ratified its auditor and elected its board of directors.
🚩 Red Flags
- Increase in authorized shares often precedes dilutive equity offerings, which is a common risk for micro-cap companies.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation to increase authorized shares of common and preferred stock (Proposal 3).
- The amendment was filed with the Secretary of State of Delaware on June 17, 2026.
- Forvis Mazars, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Seven directors were elected to the board.
- Stockholders approved 'Say-on-Pay' and voted for an annual frequency for future executive compensation votes.
Dogwood Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on May 14, 2026, to report results for the quarter ended March 31, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the operations was included as Exhibit 99.1.
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Dogwood Therapeutics, Inc. released a shareholder letter on March 26, 2026, providing a corporate update to investors. The information was furnished as a Regulation FD disclosure and is not deemed 'filed' for legal liability purposes.
📋 Key Facts
- Shareholder letter dated March 26, 2026, was posted to the company website.
- The filing includes a corporate update intended for shareholders.
- Information is furnished under Item 7.01 and is not incorporated by reference into Securities Act filings.
Dogwood Therapeutics, Inc. (DWTX) announced its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 18, 2026, to report results for the period ended December 31, 2025.
- The company furnished the information under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial performance was included as Exhibit 99.1.
- The company is a Delaware corporation trading on the Nasdaq Capital Market.
Dogwood Therapeutics held a Special Meeting on March 11, 2026, where shareholders approved the potential exercise of unregistered common stock warrants for up to 4,386,037 shares. This approval was required to comply with Nasdaq Listing Rule 5635(d) following a Securities Purchase Agreement with a single institutional investor dated January 11, 2026.
📋 Key Facts
- Special Meeting held on March 11, 2026, with 88.03% of voting power represented.
- Shareholders approved the issuance of up to 4,386,037 shares of common stock upon the exercise of warrants.
- The warrants were issued pursuant to a Securities Purchase Agreement dated January 11, 2026, with a single institutional investor.
- Approval satisfies Nasdaq Listing Rule 5635(d) regarding the issuance of 20% or more of the company's outstanding common stock.
- Proposal 1 received 29,286,786 'For' votes versus 19,057 'Against' votes.
Dogwood Therapeutics, Inc. filed an 8-K to furnish a shareholder letter containing a corporate update via Regulation FD disclosure.
📋 Key Facts
- The company issued a shareholder letter dated January 20, 2026.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Information in the shareholder letter is furnished but not 'filed' for purposes of Section 18 liability.
Dogwood Therapeutics completed a $12.5 million registered direct offering and concurrent private placement involving common stock and warrants. The company also terminated an existing At-the-Market (ATM) equity distribution agreement with Northland Securities.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 4.3 million common stock warrants and 2 million pre-funded warrants.
- Warrants include a 'downside' mechanism where exercise is subject to shareholder approval and specific ownership caps (9.99% for pre-funded, 4.99% for common).
- Termination of the existing ATM program suggests a shift in financing strategy or preference for this larger, single-investor institutional placement.
- High placement agent fees (7.0% cash + expenses) are standard but impactful on net proceeds.
📋 Key Facts
- Completed a registered direct offering of 2,338,948 shares of common stock.
- Concurrent private placement included up to 2,047,089 pre-funded warrants and 4,386,037 common stock warrants.
- Total expected gross proceeds from the offering are approximately $12.5 million before fees.
- The combined offering price for shares and accompanying warrants is $2.85 per unit.
- Maxim Group LLC acted as the sole placement agent with a 7.0% cash fee plus up to $75,000 in expense reimbursement.
- Terminated an Equity Distribution Agreement (ATM program) with Northland Securities effective January 9, 2026.
- The offering closed on January 13, 2026.
Dogwood Therapeutics, Inc. entered into an Equity Distribution Agreement with Northland Securities, Inc. to establish an 'at-the-market' (ATM) offering program. The company intends to sell up to $8,558,712 in common stock through this arrangement.
🚩 Red Flags
- Significant dilution potential: The ATM program allows for the issuance of shares representing over 21% of non-affiliate float.
- Micro-cap financing pattern: Use of an ATM program is a common method for cash-strapped micro-cap companies to raise working capital, often leading to downward pressure on stock price.
📋 Key Facts
- Entered into an Equity Distribution Agreement on November 28, 2025.
- Sales Agent: Northland Securities, Inc. (Northland Capital Markets).
- Aggregate offering amount: up to $8,558,712.
- The offering represents approximately 21.38% of the value of the Company’s outstanding common stock held by non-affiliates.
- Sales Agent commission is set at 3.0% of gross offering proceeds.
- Shares will be issued under an existing shelf registration statement (Form S-3) effective as of June 2, 2025.
Dogwood Therapeutics held a special meeting of stockholders on November 21, 2025, where shareholders approved several key matters, including the expansion of an equity incentive plan and the conversion of various series of preferred stock. Notably, the approval of these conversions completes the company's business combination with Sealbond Limited.
🚩 Red Flags
- Significant dilution potential: The equity incentive plan was expanded by over 1,400% (from ~191k to ~2.97M shares).
- Heavy reliance on convertible preferred stock structures which typically lead to significant common shareholder dilution upon conversion.
📋 Key Facts
- Special Meeting held on November 21, 2025; quorum reached with 820,239 shares (35.76% of voting power).
- Stockholders approved the Second Amended and Restated Equity Incentive Plan, increasing reserved shares from 191,122 to 2,972,787.
- Approval of conversion of Series A, A-1, and A-2 Non-Voting Convertible Preferred Stock pursuant to Nasdaq Listing Rule 5635.
- The business combination with Sealbond Limited is now officially complete following the approval of preferred stock conversions.
Dogwood Therapeutics, Inc. filed an 8-K to announce its third quarter 2025 results of operations for the period ended September 30, 2025.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 6, 2025.
- The company is an emerging growth company.
Dogwood Therapeutics, Inc. filed an 8-K to furnish a corporate presentation to its website under Regulation FD. The filing does not contain material financial changes or structural shifts.
📋 Key Facts
- The company posted a presentation to its website on October 9, 2025.
- The presentation is intended for use with investors, analysts, collaborators, and vendors.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Dogwood Therapeutics entered into an exclusive licensing agreement with Serpin Pharma and Rejuvenation Labs for the development of SP16, a LRP1 agonist. The deal involves significant equity issuance and multiple stockholder support agreements to address Nasdaq compliance issues.
🚩 Red Flags
- Significant dilution risk due to the issuance of large amounts of common and preferred stock.
- Nasdaq compliance issues: The filing explicitly mentions 'potential issuance of our Common Stock' in relation to Nasdaq Listing Rule 5635, requiring stockholder approval for various series of Preferred Stock conversions.
- Highly dilutive conversion ratio: Series A-2 Preferred Stock converts at a rate of 10,000 shares per single preferred share.
- Multiple items in a single filing (Items 1.01, 3.02, 3.03, 5.03, 7.01) indicating complex corporate restructuring/financing.
📋 Key Facts
- Entered into Exclusive Licensing Agreement with Serpin Pharma Inc. and Rejuvenation Labs, Inc. on September 29, 2025.
- Licensing terms: Royalty-free, sublicensable global license for SP16 (intravenous formulation) to treat chemotherapy-induced peripheral neuropathy.
- Consideration: Issuance of 382,034 shares of Common Stock and 179.1878 shares of Series A-2 Non-Voting Convertible Preferred Stock split between Serpin Pharma and Rejuvenation Labs.
- Tungsten Advisors received 10.8694 shares of Series A-2 Preferred Stock as compensation for financial advisory services.
- The company entered into multiple stockholder support agreements (Serpin, Tungsten, and Sealbond Limited) to vote in favor of various proposals including Nasdaq Rule 5635 compliance matters.
- Series A-2 Preferred Stock includes a conversion feature where each share converts into 10,000 shares of Common Stock upon approval of a Conversion Proposal.
Dogwood Therapeutics, Inc. filed an 8-K to announce its second quarter 2025 results of operations for the period ended June 30, 2025.
📋 Key Facts
- Report date: August 13, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing is an announcement of results of operations via press release (Exhibit 99.1)
- Company is classified as an emerging growth company
Dogwood Therapeutics announced a base salary increase for Chief Financial Officer Angela Walsh, effective July 1, 2025. The adjustment is intended to align her compensation with peer company benchmarks.
📋 Key Facts
- Effective date of salary change: July 1, 2025.
- CFO Angela Walsh's base salary increased from $279,916 to $321,903 per year.
- The increase was approved by the Board of Directors on June 27, 2025.
- Reason for change: Review of base salary levels among peer companies.
Dogwood Therapeutics held its annual meeting of stockholders on June 18, 2025. Shareholders approved the election of seven directors and an amendment to the company's Equity Incentive Plan.
🚩 Red Flags
- Historical context: The company underwent a significant 25-for-1 reverse stock split in October 2024, which is often a sign of extreme share price distress/delisting avoidance.
📋 Key Facts
- Annual Meeting held on June 18, 2025, with a quorum representing 48.22% of voting power.
- Stockholders approved Amendment No. 2 to the Amended and Restated Equity Incentive Plan, increasing reserved shares from 82,500 to 191,112.
- Seven directors were elected: Abel De La Rosa, Greg Duncan, David Keefer, John C. Thomas, Jr., Melvin Toh, Richard J. Whitley, and Alan Yu.
- Ratification of Forvis Mazars, LLP as independent registered public accounting firm for FY 2025.
- The Equity Incentive Plan includes automatic adjustments following a 25-for-1 reverse stock split on October 9, 2024.
Dogwood Therapeutics, Inc. filed an 8-K to announce its quarterly results of operations for the first quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of Q1 2025 financial results.
- Results were announced via press release on May 8, 2025.
- The company is an emerging growth company.
Dogwood Therapeutics, Inc. has announced that it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million following a debt-for-equity swap and a recent stock offering. The company remains under monitoring by Nasdaq to ensure sustained compliance.
🚩 Red Flags
- History of non-compliance with Nasdaq listing rules regarding minimum stockholders' equity.
- Significant debt restructuring involving the issuance of convertible preferred stock (potential future dilution).
- Ongoing monitoring by Nasdaq; failure to maintain compliance in next periodic report could lead to delisting.
📋 Key Facts
- The Company was notified on Nov 15, 2024, that it fell below the $2.5M minimum stockholders' equity requirement (Nasdaq Rule 5550(b)(1)).
- On March 12, 2025, the Company entered a Debt Exchange and Cancellation Agreement with Conjoint, Inc., exchanging Series A-1 Non-Voting Convertible Preferred Stock for $19.9 million in debt cancellation.
- On March 12, 2025, the Company completed a stock offering to institutional investors, raising approximately $4.8 million in gross proceeds.
- The company believes these actions have restored compliance with the stockholders' equity requirement as of April 3, 2025.
Dogwood Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period covered: Q4 and Full Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
- Company is classified as an emerging growth company.
Dogwood Therapeutics, Inc. entered into a registered direct offering to sell 578,950 shares of common stock for approximately $4.8 million in gross proceeds. The funds are intended to support the clinical development of its lead candidate, Halneuron®, and provide working capital.
🚩 Red Flags
- Dilution: The issuance of 578,950 new shares will dilute existing shareholders.
- Cash Burn/Funding Need: The necessity to raise capital for 'working capital' and clinical development suggests ongoing cash burn typical of biotech micro-caps.
📋 Key Facts
- Offered 578,950 shares of common stock at a price of $8.26 per share.
- Total gross proceeds from the offering are approximately $4.8 million.
- The offering closed on March 14, 2025.
- Maxim Group LLC acted as the sole exclusive placement agent with a 7.0% fee.
- The company is subject to a 30-day standstill period regarding further equity issuances or variable rate transactions.
Dogwood Therapeutics has entered into a debt exchange agreement to convert approximately $19.9 million in debt into Series A-1 Non-Voting Convertible Preferred Stock. As part of this restructuring, the company's financial advisor has signed support agreements to facilitate a potential reverse stock split required to maintain Nasdaq listing compliance.
🚩 Red Flags
- Potential reverse stock split explicitly mentioned to maintain Nasdaq compliance.
- Significant dilution risk: Each preferred share converts into 10,000 common shares.
- Debt restructuring indicates liquidity/solvency pressures.
- Non-voting preferred stock issuance suggests the company is seeking capital relief without giving up control, but at high cost of future dilution.
📋 Key Facts
- The Company exchanged $19,926,891 in debt (principal and accrued interest) for 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock.
- The conversion price was determined based on the average Nasdaq closing price over the five trading days prior to March 12, 2025 ($7.01 per underlying common share).
- Each share of Series A-1 Preferred Stock is convertible into 10,000 shares of Common Stock.
- The company's financial advisor (Tungsten Advisors LLC) signed support agreements to vote in favor of the conversion and a potential reverse stock split.
- Series A-1 Preferred Stock has no voting rights but includes protective provisions regarding fundamental transactions and charter amendments.
Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed this 8-K/A to amend a previous filing regarding the acquisition of 100% of Pharmagesic (Holdings) Inc. via a Share Exchange Agreement with Sealbond Limited. The amendment provides the required audited financial statements and pro forma information for the acquired entity.
🚩 Red Flags
- The filing is an amendment (8-K/A) to correct a previous omission of required financial statements and pro forma information.
- Complexity of the ownership structure involving BVI and Hong Kong listed entities can increase transparency risks in micro-cap environments.
📋 Key Facts
- Acquisition of 100% of issued and outstanding common shares of Pharmagesic (Holdings) Inc., a Canadian corporation.
- The transaction was executed via a Share Exchange Agreement with Sealbond Limited, a BVI corporation.
- Pharmagesic was previously a subsidiary of Sealbond and indirectly owned by CK Life Sciences Int’l. (Holdings) Inc. (listed on the Hong Kong Stock Exchange).
- Includes audited financial statements for Pharmagesic for years ended Dec 31, 2023, and 2022.
- Includes unaudited interim financial statements for Pharmagesic for nine months ended Sept 30, 2024, and 2023.
Dogwood Therapeutics received a notice from Nasdaq stating it is non-compliant with minimum stockholders' equity requirements. The company must submit a compliance plan by December 30, 2024.
🚩 Red Flags
- Delisting notice received from Nasdaq
- Stockholders' equity is below the $2.5M minimum threshold
- Failure to meet alternative listing standards (market value and net income)
- Potential for a 180-day extension period or appeal process, indicating high uncertainty regarding continued listing.
📋 Key Facts
- Nasdaq notified the company on November 15, 2024, of non-compliance with Nasdaq Listing Rule 5550(b)(1).
- The deficiency is due to stockholders' equity falling below the $2,500,000 minimum requirement.
- The determination was based on Form 10-Q data for the period ended September 30, 2024.
- The company does not meet alternative compliance standards regarding market value of listed securities or net income from continuing operations.
- The company has until December 30, 2024, to submit a plan to regain compliance.
Dogwood Therapeutics, Inc. filed an 8-K to announce its third quarter 2024 financial results for the period ended September 30, 2024.
📋 Key Facts
- The filing was made on November 7, 2024.
- The report covers the third quarter ended September 30, 2024.
- Results were announced via a press release included as Exhibit 99.1.
Dogwood Therapeutics, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company successfully met the ten-consecutive-business-day threshold required by the Hearing Panel's decision from June 2024.
🚩 Red Flags
- Historical delisting risk (the company was previously under scrutiny for failing to meet minimum bid requirements).
📋 Key Facts
- The Company received a letter from Nasdaq confirming compliance with Listing Rule 5550(a)(2).
- Compliance was achieved after the common stock maintained a closing bid price of at least $1.00 for ten consecutive business days.
- The matter regarding the minimum bid price requirement is now officially closed.
Virios Therapeutics entered into a definitive agreement to acquire 100% of Pharmagesic (Holdings) Inc. via a share exchange, which includes a significant $19.5 million loan for operations and R&D.
🚩 Red Flags
- Potential reverse stock split mentioned as a possibility to maintain Nasdaq compliance.
- Significant dilution via Series A Preferred Stock convertible into 10,000 shares of common stock per share.
- The combination is described as a 'change of control' under Nasdaq rules, requiring stockholder approval.
- High debt load/liquidity dependency: $19.5M loan from an affiliate (Conjoint Inc.) to fund operations.
📋 Key Facts
- Acquisition of 100% of Pharmagesic (Holdings) Inc. from Sealbond Limited via Share Exchange Agreement.
- Issuance of up to 19.99% of common stock and Series A Non-Voting Convertible Preferred Stock to Sealbond.
- Company will change its name to 'Dogwood Therapeutics, Inc.' following the combination.
- Entered into a $19.5 million Loan Agreement with Conjoint Inc. ($16.5M disbursed Oct 7, 2024; $3M in Feb 2025).
- Issuance of Contingent Value Rights (CVR) to existing shareholders for 87.75% of any future upfront or milestone payments.
- Lock-up agreements established for Sealbond and company directors/officers for 180 days.
Virios Therapeutics, Inc. filed an 8-K to announce its second quarter 2024 financial results for the period ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly results (Item 2.02).
- Reporting period: Second Quarter ended June 30, 2024.
- Filing date: August 8, 2024.
Virios Therapeutics, Inc. held its annual meeting of stockholders on June 18, 2024, where all proposed matters were approved by shareholders.
📋 Key Facts
- Annual Meeting held on June 18, 2024.
- Quorum established with 8,699,494 shares (45.17% of voting power) present in person or by proxy.
- Six nominees were elected to the Board of Directors: Richard Burch, Abel De La Rosa, Ph.D., Greg Duncan, David Keefer, John C. Thomas, Jr., and Richard J. Whitley, M.D.
- Shareholders ratified the appointment of FORVIS, LLP as independent registered public accounting firm for fiscal year ending December 31, 2024.
Virios Therapeutics received an extension from the Nasdaq Hearing Panel to regain compliance with the $1.00 minimum bid price requirement by October 28, 2024. If the company fails to comply by the October deadline, it will be required to undergo a reverse stock split or face delisting.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Imminent threat of a reverse stock split to maintain listing
- History of failing Nasdaq compliance periods (initial 180-day period expired April 30, 2024)
📋 Key Facts
- Nasdaq Hearing Panel granted an exception until October 28, 2024, to regain compliance with the $1.00 minimum bid price requirement.
- The company must achieve compliance by October 11, 2024, or it will be required to undertake a reverse stock split to meet the October 28 deadline.
- Failure to regain compliance by October 28, 2024, will result in delisting from the Nasdaq Capital Market.
- The company previously failed its initial 180-day compliance period which ended on April 30, 2024.
Virios Therapeutics, Inc. entered into a placement agency agreement with Maxim Group LLC to conduct a public offering of 8,500,000 shares of common stock at $0.20 per share. The offering is intended to raise gross proceeds of approximately $1.7 million.
🚩 Red Flags
- Significant dilution: The issuance of 8.5 million shares at a very low price point ($0.20) suggests a highly dilutive capital raise.
- Low share price: Pricing at $0.20 is characteristic of micro-cap companies facing liquidity constraints or struggling to maintain minimum bid requirements.
📋 Key Facts
- Offering size: 8,500,000 shares of common stock.
- Public offering price: $0.20 per share.
- Expected closing date: On or about May 22, 2024.
- Placement agent fee: 8.0% of gross proceeds plus reimbursement of expenses/legal fees up to $75,000.
- The offering is being conducted pursuant to an effective shelf registration statement on Form S-3.
Virios Therapeutics, Inc. filed an 8-K to announce its quarterly results of operations for the first quarter ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of Q1 2024 financial results.
- Report date: May 9, 2024.
- Results cover the period ending March 31, 2024.
Virios Therapeutics, Inc. has failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement as of May 1, 2024. The company has requested a hearing with the Nasdaq Hearings Panel to seek an extension and stay the delisting process.
🚩 Red Flags
- Delisting notice/failure to satisfy continued listing rule
- Failure to meet minimum bid price requirement ($1.00)
- Potential reverse stock split mentioned as a remedial measure
- Ongoing uncertainty regarding Nasdaq Hearings Panel decision
📋 Key Facts
- The company received notice on May 1, 2024, that it failed to comply with the $1.00 minimum bid price requirement.
- A previous compliance period was set to expire on April 30, 2024.
- The company has requested a hearing with the Nasdaq Hearings Panel to stay delisting.
- Management intends to propose a plan for compliance that includes a potential reverse stock split if necessary.
- Compliance efforts are tied to anticipated data from the IMC-2 study for Long-COVID being conducted by the Bateman Horne Center.
Virios Therapeutics, Inc. held a special meeting of stockholders on March 1, 2024, where shareholders approved a proposal for a reverse stock split and the adjournment of the meeting to solicit additional proxies if necessary.
🚩 Red Flags
- Approval of a reverse stock split is often used to regain compliance with minimum bid price requirements for exchange listing (Nasdaq).
- Significant opposition to the reverse stock split (approx. 38% of votes cast against).
📋 Key Facts
- Special Meeting held on March 1, 2024.
- Quorum established by 12,438,213 shares (64.58% of voting power) as of the January 30, 2024 record date.
- Proposal 1 (Reverse Stock Split) was approved with 7,553,703 votes in favor and 4,697,955 against.
- Proposal 2 (Adjournment of Special Meeting to solicit additional proxies if needed) was also approved.
Virios Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Reported date: February 29, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing is a standard earnings release under Item 2.02.
Virios Therapeutics announced a company-wide 10% reduction in cash compensation for all employees and executive officers, effective March 1, 2024. To offset these cuts, the Board approved stock option grants to executives and directors that vest in full on February 26, 2025.
🚩 Red Flags
- Significant reduction in cash compensation often signals liquidity constraints or a need for immediate cost-cutting.
- Full vesting of stock options in a single day (February 26, 2025) creates a potential 'cliff' and future dilution pressure.
📋 Key Facts
- Board approved a 10% salary reduction for all employees and executive officers effective March 1, 2024.
- Board approved a 10% reduction in cash compensation for non-employee directors.
- Stock options were granted to executives and directors with an exercise price of $0.357 per share.
- The granted stock options are set to vest in full on February 26, 2025.
Virios Therapeutics, Inc. filed an 8-K to furnish a shareholder letter issued on January 3, 2024, pursuant to Regulation FD disclosure requirements.
📋 Key Facts
- The filing is made under Item 7.01 (Regulation FD Disclosure).
- A shareholder letter dated January 3, 2024, was issued as Exhibit 99.1.
- Information furnished under Item 7.01 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.